Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ruxolitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 15/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 14/20 | 1.00 |
| ▸ | JAK3 | P52333 | 6/20 | 1.00 |
| ▸ | ABL1 | P00519 | 3/20 | 1.00 |
| ▸ | TYK2 | P29597 | 3/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | PAK4 | O96013 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | LTK | P29376 | 2/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 1.00 |
| ▸ | CLK2 | P49760 | 2/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 2/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 2/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 2/20 | 1.00 |
| ▸ | IKBKE | Q14164 | 2/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 2/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 2/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 1.00 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 1.00 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ruxolitinib SCHEMBL29677353 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL26927161 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL99225 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL101279 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL31247553 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL171319 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL26927158 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL29808249 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| SCHEMBL99371 | 0.99 | JAK2 (0.98) | JAK2JAK1JAK3ABL1TYK2 | |
| SCHEMBL99245 | 0.99 | JAK2 (0.98) | JAK2JAK1JAK3ABL1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12245 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4746973-A1 | METHODS OF TREATING CHRONIC GRAFT-VERSUS-HOST DISEASE USING AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY | Incyte Corporation (US) | 2026-05-27 | — | — | EP | claimed |
| US-12635917-B2 | Remote blood volume monitor | DAXOR CORP. (US) | 2026-05-26 | — | — | US | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026107085-A1 | METHODS OF TREATING LUPUS WITH CD19-CD20 DUAL CAR-T CELLS | GENENTECH, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| WO-2026107075-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS WITH CD19-CD20 DUAL CAR-T CELLS | GENENTECH, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137695-A1 | COMBINATION THERAPY FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | INCYTE CORP (US) | 2026-05-21 | — | — | US | claimed |
| WO-2022022624-A1 | METHOD FOR PRODUCING CARDIOMYOCYTES BY MEANS OF REPROGRAMMING | 南京昕瑞再生医药科技有限公司 | 2022-02-03 | — | — | WO | claimed |
| WO-2022023759-A2 | METHODS OF PREPARING SOLID PARTICULATE MATERIALS | MICROPORE TECHNOLOGIES LIMITED (GB) | 2022-02-03 | — | — | WO | claimed |
| WO-2022023490-A1 | METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS | ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) | 2022-02-03 | — | — | WO | claimed |
| EP-3944859-A1 | METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS | Assistance Publique Hôpitaux de Paris (FR) | 2022-02-02 | — | — | EP | claimed |
| US-11234983-B2 | JAK inhibition as a novel therapy for preventing tumors in Peutz-Jeghers Syndrome | Curingenetics, LLC (US) | 2022-02-01 | — | — | US | claimed |
| WO-2022016844-A1 | INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION | 厦门特宝生物工程股份有限公司 | 2022-01-27 | — | — | WO | claimed |
| EP-3941474-A2 | BIOMARKERS FOR VITILIGO | Incyte Corporation (US) | 2022-01-26 | — | — | EP | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
| US-11229653-B2 | Methods of treatment of myeloproliferative neoplasm | CELGENE CORPORATION (US) | 2022-01-25 | — | — | US | claimed |
| CN-113952460-A | Compound external preparation for treating alopecia areata and preparation method thereof | 长沙晶易医药科技有限公司 | 2022-01-21 | — | — | CN | claimed |